Lilly Introduces AI Platform TuneLab for Biotech Drug Discovery

Lilly has launched Lilly TuneLab, an AI and machine learning platform designed to provide biotechnology companies with access to advanced drug discovery models. Announced in a press release, the platform utilizes proprietary data accumulated through over $1 billion in research investment.

Lilly TuneLab aims to democratize access to AI capabilities by allowing smaller biotech firms to use the same models employed by Lilly scientists. The platform is powered by comprehensive datasets covering drug disposition, safety, and preclinical data from hundreds of thousands of unique molecules. It employs federated learning to ensure privacy, enabling biotech partners to contribute training data without exposing proprietary information.

This initiative is part of Lilly Catalyze360, which supports early-stage drug development through strategic capital, laboratory facilities, and drug development expertise. Lilly plans to expand TuneLab's features, including adding predictive models for small molecules, exclusively available on the platform.